Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Dominik Witzigmann
Advertisement
Dominik Witzigmann, PhD, is co-founder and president of NanoVation Therapeutics.
Articles by Dominik Witzigmann
Advertisement
Latest Updated Articles
Advertisement
Advertisement